still can enter?_老虎社区_美港股上老虎

dripdd
2021-05-04

still can enter?

After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>继昨天飙升近24%后，OCGN在盘前交易中下跌4%</blockquote>

(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares

After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>继昨天飙升近24%后，OCGN在盘前交易中下跌4%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":106219086,"tweetId":"106219086","gmtCreate":1620122180545,"gmtModify":1634207656811,"author":{"id":3574719738695807,"idStr":"3574719738695807","authorId":3574719738695807,"authorIdStr":"3574719738695807","name":"dripdd","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>still can enter?</body></html>","htmlText":"<html><head></head><body>still can enter?</body></html>","text":"still can enter?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/106219086","repostId":1157490418,"repostType":4,"repost":{"id":"1157490418","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620120727,"share":"https://www.laohu8.com/m/news/1157490418?lang=zh_CN&edition=full","pubTime":"2021-05-04 17:32","market":"us","language":"en","title":"After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>继昨天飙升近24%后，OCGN在盘前交易中下跌4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157490418","media":"Tiger Newspress","summary":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares ","content":"(May 4)&nbsp;After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.<blockquote>（5月4日）继昨日飙升近24%后，OCGN在盘前交易中下跌4%。</blockquote><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\">What happened<blockquote>发生了什么</blockquote>Shares of&nbsp;Ocugen(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.<blockquote>本公司之股份奥库根（纳斯达克：OCGN）周一飙升23.8%，此前这家生物技术公司发布了Covaxin研究的有希望的数据，该公司希望将Covaxin引入美国市场。</blockquote>So what<blockquote>那又怎样</blockquote>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.<blockquote>印度医学研究委员会（ICMR）-国家病毒学研究所的研究人员认为，科瓦克辛可以预防多种冠状病毒株。科瓦克辛似乎对来自巴西的一种名为B.1.128.2的变种有效。此前的一项研究表明，科瓦克辛还可以预防来自英国和印度的变种。</blockquote>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"<blockquote>Ocugen联合创始人兼首席执行官Shankar Musunuri博士在一份新闻稿中表示：“科瓦克辛在迄今为止进行的所有研究中继续显示出强劲的结果。”“我们仍然相信，这种疫苗是我们国家武器库中抗击这一流行病的重要工具。”</blockquote>Now what<blockquote>现在怎么办</blockquote>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.<blockquote>Musunuri表示，Ocugen向美国提交了一份全面的药物主文件。美国食品药品监督管理局（FDA）。该公司还在准备紧急使用授权的申请。Ocugen与其药物开发合作伙伴、总部位于印度的Bharat Biotech达成的协议规定，如果获得监管授权，该公司将获得在美国销售科瓦克辛利润的45%份额。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>继昨天飙升近24%后，OCGN在盘前交易中下跌4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>继昨天飙升近24%后，OCGN在盘前交易中下跌4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-05-04 17:32\n</div>\n</a>\n</h4>\n</header>\n<article>\n(May 4)&nbsp;After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.<blockquote>（5月4日）继昨日飙升近24%后，OCGN在盘前交易中下跌4%。</blockquote><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\">What happened<blockquote>发生了什么</blockquote>Shares of&nbsp;Ocugen(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.<blockquote>本公司之股份奥库根（纳斯达克：OCGN）周一飙升23.8%，此前这家生物技术公司发布了Covaxin研究的有希望的数据，该公司希望将Covaxin引入美国市场。</blockquote>So what<blockquote>那又怎样</blockquote>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.<blockquote>印度医学研究委员会（ICMR）-国家病毒学研究所的研究人员认为，科瓦克辛可以预防多种冠状病毒株。科瓦克辛似乎对来自巴西的一种名为B.1.128.2的变种有效。此前的一项研究表明，科瓦克辛还可以预防来自英国和印度的变种。</blockquote>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"<blockquote>Ocugen联合创始人兼首席执行官Shankar Musunuri博士在一份新闻稿中表示：“科瓦克辛在迄今为止进行的所有研究中继续显示出强劲的结果。”“我们仍然相信，这种疫苗是我们国家武器库中抗击这一流行病的重要工具。”</blockquote>Now what<blockquote>现在怎么办</blockquote>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.<blockquote>Musunuri表示，Ocugen向美国提交了一份全面的药物主文件。美国食品药品监督管理局（FDA）。该公司还在准备紧急使用授权的申请。Ocugen与其药物开发合作伙伴、总部位于印度的Bharat Biotech达成的协议规定，如果获得监管授权，该公司将获得在美国销售科瓦克辛利润的45%份额。</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157490418","content_text":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares of Ocugen(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.So whatResearchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"Now whatMusunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2887,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}